Research programme: cancer therapeutics - OncoMed

Drug Profile

Research programme: cancer therapeutics - OncoMed

Alternative Names: Anti-cancer stem cell monoclonal antibodies - OncoMed; Anti-CSC monoclonal antibodies - OncoMed; Anti-tumour-initiating cell monoclonal antibodies - OncoMed; GITRL-Fc; GITRL-Fc trimer - OncoMed; I/O#2; IO#2; IO#3; OMP-336B11; OMP-OMP-336B11

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Notch-1 receptor antagonists; Notch-2 receptor antagonists; Notch-3 receptor antagonists; RSPO3 protein inhibitors; Stem cell modulators; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2017 OncoMed plans to file an IND application with the US FDA for its GITRL-Fc trimer immuno-oncology agent in Cancer
  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 05 Jan 2017 OncoMed intends to file an IND application for OMP 336B11 for Cancer in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top